Corindus Vascular Robotics (NYSE:CVRS) moved to forestall a group of lawsuits brought over its pending $1.1 billion merger with Siemens Healthineers (NYSE:SI). Corindus announced August 9 that it was set to be acquired by Siemens in an all-cash deal for $4.28 per CVRS share. The announcement prompted six lawsuits alleging that Corindus provided incomplete and misleading financial projections […]
Corindus Vascular Robotics
First remote robotic PCI surgeries performed in India
A cardiologist in India has performed the first remote robot-assisted percutaneous coronary intervention procedures (R-PCIs), according to a new study published this week. The cardiologist used Corindus Vascular Robotics‘ CorPathGRX system and performed the five successful procedures from 20 miles away, according to an article on the study published in The Lancet’s EClinicalMedicine. The primary […]
FTC clears $1.1B Corindus buyout by Siemens Healthineers
Corindus Vascular Robotics (NYSE:CVRS) said today that the U.S. Federal Trade Commission granted early termination of the waiting period on its $1.1 billion acquisition by Siemens Healthineers (NYSE:SI). The all-cash deal for Waltham, Mass.-based Corindus, which is developing a robot-assisted device for vascular procedures, calls for the German conglomerate’s healthcare arm to pony up $4.28 per share. […]
Siemens to acquire Corindus in $1.1B deal
Corindus Vascular Robotics (NYSE:CVRS) reported its second-quarter financials today, revealing that it inked a deal to be acquired by Siemens Healthineers (NYSE:SI) in an all-cash deal valued at roughly $1.1 billion. Siemens Medical Solution, a subsidiary of Siemens Healthineers, is slated to acquire all issued and outstanding common stock in Corindus for $4.28 apiece in cash. The […]
EuroPCR 2019: Elixir Medical touts DynamX
Elixir Medical touted clinical and imaging results from a study of its DynamX drug-eluting stent, which is designed to restore normal pulsatility and adaptive remodeling in blood vessels after treating a coronary lesion. DynamX, introduced in 2017 at the annual Transcatheter Cardiovascular Therapeutics meeting, is a cobalt-chromium stent with a biodegradable polymer coating that releases novolimus. […]
Corindus Vascular Robotics shares rising despite Q1 EPS, sales miss
Shares in Corindus Vascular Robotics (NYSE:CVRS) are up over 15% today after the surgical robotic platform maker posted first quarter 2018 earnings that missed both sales and loss-per-share consensus on Wall Street. The Waltham, Mass.-based company posted losses of approximately $9.7 million, or 5¢ per share, on sales of approximately $3 million for the three months […]
Corindus touts first Japanese CorPath GRX procedures
Corindus Vascular Robotics (NYSE:CVRS) said today that the first Japanese procedures using its CorPath GRX robot-assisted device took place as part of a post-market surveillance study. Waltham, Mass.-based Corindus, which last June won clearance from Japan’s Pharmaceutical & Medical Device Agency for CorPath GRX, inked a distribution deal for Japan in February 2017 that included a […]
Corindus Vascular Robotics meets The Street with Q4 earnings
Corindus Vascular Robotics (OTC:CVRS) shares gained today after the robot-assisted surgery company reported fourth-quarter results that met the forecast on Wall Street. Losses grew 3.1% for Waltham, Mass.-based Corindus posted to -$8.2 million, or -4¢ per share, on sales growth of 11.5% to $4.7 million for the three months ended Dec. 31, 2018, compared with […]
Corindus adds $5m to private placement
Corindus Vascular Robotics (OTC:CVRS) said today that it added onto a previously closed private placement, bringing in an additional $4.8 million. The Waltham, Mass.-based company said that in the additional closing, it floated 3.5 million shares of its stock at a price of approximately $1.38 per share. The placement included participation from Hudson Executive Capital and […]
Corindus closes $15m private placement
Corindus Vascular Robotics (OTC:CVRS) said today that it closed a $15 million private placement round. The Waltham, Mass.-based medical robotics company said it sold a total of approximately 10.9 million shares of its common stock at a purchase price of approximately $1.38 per share, for aggregate proceeds of approximately $15 million. Net proceeds from the private […]
Corindus asks FDA for expanded neurosurgery indication for CorPath GRX
Corindus Vascular Robotics (OTC:CVRS) said today that it submitted an application seeking FDA premarket clearance to use its CorPath GRX robotic surgical platform in neurovascular interventions. The Waltham, Mass.-based company has already received FDA clearance for percutaneous coronary interventions, which it won in 2016, and for peripheral vascular interventions, which it won last year. “The ability to […]
